Helen Torley

Director, President & Chief Executive Officer at Halozyme Therapeutics, Inc.

Helen Torley

Helen Torley

Director, President & Chief Executive Officer at Halozyme Therapeutics, Inc.

Overview
Career Highlights

Halozyme Therapeutics, Inc.

RelSci Relationships

3054

Number of Boards

6

Birthday

1963

Age

58

Contact Data
Trying to get in touch with Helen Torley? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Helen Torley likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former National President at Girl Scouts of the USA

Relationship likelihood: Strong

Chief Strategist at Deepcell

Relationship likelihood: Strong

Former President at Cardinal Health Systems, Inc.

Relationship likelihood: Strong

Former Chief Financial Officer at INAMED Corp.

Relationship likelihood: Strong

Founder at Third Security LLC

Relationship likelihood: Strong

Former Vice President & General Manager-Oncology Business Unit at Amgen, Inc.

Relationship likelihood: Strong

President & Director at Synergie Lyon Cancer

Relationship likelihood: Strong

Fellow at Harvard University Advanced Leadership Initiative

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Nkarta, Inc.

Relationship likelihood: Strong

Senior Vice President & Chief Technical Officer at Halozyme Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Helen Torley
Potential Connections via
Relationship Science
You
Helen Torley
Director, President & Chief Executive Officer at Halozyme Therapeutics, Inc.
Education
Bachelor of Medicine & Bachelor of Surgery (M.B. Ch. B.)
Memberships
Career History
Chief Commercial Officer & Executive Vice President
2011 - 2014

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. At Onyx, we are grounded in three leadership hallmarks that guide how we manage our business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.

Vice President, Cardiovascular & Metabolic Sales
1997 - 2002

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Head, Nephrology Business Unit
2003 - 2011

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Boards & Committees
Member, Board of Directors
2018 - Current
President, Chief Executive Officer & Director
2014 - Current
Independent Director
2015 - 2016
At-Large Member, Board of Directors
Current
Director
Prior
Political Donations
Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Helen Torley. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Helen Torley's profile does not indicate a business or promotional relationship of any kind between RelSci and Helen Torley.